Moreover, NEK2 – a well-established transcriptional target of FOXM1 in cancer [61, 62] that has been shown to drive drug resistance in myeloma and other malignancies [63–65] – can be targeted with the help of small compounds that inhibit kinase activity [66] or trigger target degradation indirectly by means of a mechanism that involves the disruption of NEK2 binding to the kinetochore complex component NDC80 / HEC1 [67]. Here, NDC80 is linked to cancer.